Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

Harrison's Principles of Internal Medicine.

1988 • 11,687 citations

1969 Cancer Facts and Figures

1968 • 8,880 citations

Reporting results of cancer treatment

1981 • 7,916 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Harrison's Principles of Internal Medicine

1994 • 1,392 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

2002 • 487 citations

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1991 • 444 citations

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

2003 • 349 citations

Relationship of Mitotic Arrest and Apoptosis to Antitumor Effect of Paclitaxel

1996 • 290 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

1994 • 144 citations

Evolving concepts in the systemic drug therapy of breast cancer.

1997 • 142 citations

CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC

2004 • 131 citations

The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

1979 • 111 citations

Second-line chemotherapy and its evaluation in small cell lung cancer

1999 • 69 citations

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer

2001 • 68 citations

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

1992 • 67 citations

Single-agent gemcitabine in patients with resistant small-cell lung cancer

2001 • 65 citations

Paclitaxel in Cancer Treatment

1996 • 62 citations

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

2003 • 61 citations

CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC

2004 • 59 citations

Paclitaxel in cancer treatment

1995 • 47 citations

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer

2003 • 45 citations

Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base

1993 • 44 citations

Small Cell Lung Cancer

1995 • 43 citations

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer

2003 • 34 citations

Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer

2000 • 33 citations

Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.

1993 • 31 citations

Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts

1993 • 28 citations

Treatment of relapsed small cell lung cancer

2001 • 23 citations

Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer

2001 • 22 citations

Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

2003 • 21 citations

Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

2004 • 15 citations

Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study

2004 • 14 citations

Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study

2004 • 8 citations

A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine.

2004 • 7 citations